Abstract:Objective. Polycystic ovary syndrome (PCOS) is one of the prevalent gynecological endocrine disorders encountered in clinical practice. Women diagnosed with PCOS demonstrate increased ovarian responsiveness, rendering them more prone to ovarian hyperstimulation syndrome (OHSS) during controlled ovarian stimulation (COS) procedures. The current study aimed at investigating whether CCL25/CCR9 plays a role in the pathological process of high ovarian response (HOR) during COS procedures. Design. Single‐center retrospective cohort study. Patients. A total of 200 PCOS patients who received a fixed regimen of gonadotropin‐releasing hormone (GnRH) antagonist were enrolled in this study. The cohort comprised 118 patients exhibiting HOR and 82 patients demonstrating a normal ovarian response (NOR). Results. The age and body mass index (BMI) variances across the two groups did not differ significantly. Similarly, the two groups observed no statistically significant differences in the baseline levels of luteinizing hormone (LH), progesterone (P), estradiol (E 2 ), basal prolactin (PRL), and testosterone (T). Compared to the NOR group, HOR patients exhibit markedly elevated levels of anti‐Müllerian hormone (AMH), antral follicle count (AFC), basal follicle‐stimulating hormone (FSH), and HOMA‐IR (all p < 0.05). Conversely, no statistically significant differences were observed between the two groups with respect to COS parameters, encompassing initial gonadotropin (Gn) dose, stimulation duration, and total Gn dose. During COS, the number of oocytes with diameter ≥14 mm, the levels of E 2 on the HCG day, and the number of retrieved oocytes were significantly higher in the HOR group than in the NOR group (all p < 0.001). Additionally, the levels of CCL25/CCR9, matrix metalloproteinases (MMPs), tissue inhibitor of metalloproteinases (TIMPs), TNF‐α, and IL‐6 were significantly higher in the FF of the HOR group than in the NOR group (all p < 0. 001), while the variance in IL‐1β levels between the two cohorts did not reach statistical significance. The relevance analysis results indicated that the levels of CCL25/CCR9 in the FF of the HOR group are positively correlated with the number of retrieved oocytes and oocytes with diameters ≥14 mm during COS, AMH levels, and AFC. Concurrently, the CCL25 levels in the FF of the HOR group were positively correlated with HOMA‐IR. Multivariable linear regression analysis revealed that the elevated AFC and HOMA‐IR independently increase the CCL25 levels. Conclusion. The CCL25/CCR9 levels in FF are positively correlated with the clinical indicators of HOR, suggesting that CCL25/CCR9 may play a role in the pathogenesis of HOR in patients with PCOS.

Hyper response to ovarian stimulation affects the follicular fluid metabolomic profile of women undergoing IVF similarly to polycystic ovary syndrome

Ovarian Leukocyte Distribution and Cytokine/chemokine Mrna Expression in Follicular Fluid Cells in Women with Polycystic Ovary Syndrome.

Steroid metabolome profiling of follicular fluid in normo- and hyperandrogenic women with polycystic ovary syndrome

Metabolic landscape and pathogenic insights: a comprehensive analysis of high ovarian response in infertile women undergoing in vitro fertilization

Intrafollicular fluid metabolic abnormalities in relation to ovarian hyperstimulation syndrome: Follicular fluid metabolomics via gas chromatography-mass spectrometry

Follicular Free Fatty Acid Metabolic Signatures and Their Effects on Oocyte Competence in Non-Obese PCOS Patients

Serum Metabolomic Signature Predicts Ovarian Response to Controlled Stimulation

Serum Steroid Metabolome on the Day of Oocyte Retrieval in Women with Polycystic Ovarian Syndrome and Its Association with Pregnancy Outcome of in Vitro Fertilization.

Relationship between CCL25/CCR9 Levels in Follicular Fluid and High Ovarian Response in Patients with Polycystic Ovary Syndrome

Multi-omics approach to reveal follicular metabolic changes and their effects on oocyte competence in PCOS patients

Response of IGF and IL-6 to ovarian stimulation in PCOS and normal women

Identification of the Metabolomics Signature of Human Follicular Fluid from PCOS Women with Insulin Resistance

Anti-Müllerian hormone a surrogate of follicular fluid oxidative stress in polycystic ovary syndrome?

Metabolomic Analysis of Follicular Fluid in Normal-Weight Patients with Polycystic Ovary Syndrome

Follicular Metabolic Changes And Effects On Oocyte Quality In Polycystic Ovary Syndrome Patients

Insights into Protein Composition and Metabolic Pathway Alterations

Comparison of Endocrine Profile Andin VitroFertilization Outcome in Patients with PCOS, Ovulatory PCO, or Normal Ovaries

Cytokine profile of follicular fluid and oocyte quality of PCOS patients with metabolic syndrome

Follicular Fluid Lipidomic Profiling Reveals Potential Biomarkers of Polycystic Ovary Syndrome: A Pilot Study

Oxidative stress and polycystic ovary syndrome: evaluation during ovarian stimulation for ICSI

Biomarkers Identification in Follicular Fluid in Relation to Live Birth in in Vitro Fertilization of Women with Polycystic Ovary Syndrome in Different Subtypes by Using UPLC-MS Method